Projects per year
Fingerprint Dive into the research topics where Arthur Vandenbark is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 17 Similar Profiles
Autoimmune Experimental Encephalomyelitis
Medicine & Life Sciences
T-Lymphocytes
Medicine & Life Sciences
T-Cell Antigen Receptor
Medicine & Life Sciences
Myelin Basic Protein
Medicine & Life Sciences
Peptides
Medicine & Life Sciences
Multiple Sclerosis
Medicine & Life Sciences
Regulatory T-Lymphocytes
Medicine & Life Sciences
Encephalomyelitis
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 1979 2017
Development of DR?1-MOG-35-55 for treatment of DR2 negative MS subjects
2/1/16 → 1/31/17
Project: Research project
Multiple Sclerosis
HLA-DR2 Antigen
Autoimmune Experimental Encephalomyelitis
Peptides
Therapeutics
Myelin Sheath
Multiple Sclerosis
T-Lymphocytes
Autoimmune Experimental Encephalomyelitis
T-Cell Antigen Receptor
Ligands
Autoimmune Experimental Encephalomyelitis
T-Cell Antigen Receptor
T-Lymphocytes
Multiple Sclerosis
Multiple Sclerosis
T-Lymphocytes
Autoimmune Experimental Encephalomyelitis
Peptides
Pharmaceutical Preparations
Research Output 1974 2019
1
Citation
(Scopus)
A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury
Vandenbark, A., Meza-Romero, R., Benedek, G. & Offner, H., Jan 23 2019, In : Journal of Neuroinflammation. 16, 1, 14.Research output: Contribution to journal › Review article
Methamphetamine
Multiple Sclerosis
Central Nervous System
Wounds and Injuries
Anti-Inflammatory Agents
Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke
Seifert, H. A., Zhu, W., Vandenbark, A., Alkayed, N. & Offner, H., Jan 1 2019, (Accepted/In press) In : Metabolic brain disease.Research output: Contribution to journal › Article
T-cells
Therapeutic Uses
Neutralizing Antibodies
Sex Characteristics
Stroke
1
Citation
(Scopus)
Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells
Seifert, H. A., Benedek, G., Nguyen, H., Gerstner, G., Zhang, Y., Kent, G., Vandenbark, A., Bernhagen, J. & Offner, H., Jun 18 2018, (Accepted/In press) In : Metabolic Brain Disease. p. 1-9 9 p.Research output: Contribution to journal › Article
Autoimmune Experimental Encephalomyelitis
Anti-Inflammatory Agents
Macrophages
Anti-Bacterial Agents
Spinal Cord
Functional MRI and delay discounting in patients infected with hepatitis C
McCready, H., Kohno, M., Kolessar, M., Dennis, L., Kriz, D., Luber, H., Anderson, R., Chang, M., Sasaki, A., Flora, K., Vandenbark, A., Mitchell, S., Loftis, J., Hoffman, W. F. & Huckans, M., Jan 1 2018, (Accepted/In press) In : Journal of NeuroVirology.Research output: Contribution to journal › Article
Impulsive Behavior
Hepatitis C
Parietal Lobe
Viral Load
Reward
1
Citation
(Scopus)
Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct
Meza-Romero, R., Benedek, G., Gerstner, G., Kent, G., Nguyen, H., Offner, H. & Vandenbark, A., Jan 1 2018, (Accepted/In press) In : Metabolic Brain Disease.Research output: Contribution to journal › Article
Autoimmune Experimental Encephalomyelitis
Multiple Sclerosis
Macrophage Migration-Inhibitory Factors
Cell Surface Receptors
Neurology